Inventor · disambiguated record
Ka-Man Venus Lai
Also filed as: LAI KA-MAN VENUS
55 granted patents·23 pending applications·534 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
78 records- 0199US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 0299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 0398US10385359B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2017·Granted Aug 20, 2019·29 cites·39 claims
- 0498US10329582B2Genetic modification of ratsREGENERON PHARMA·Filed 2016·Granted Jun 25, 2019·25 cites·37 claims
- 0598US10208317B2Methods and compositions for the targeted modification of a mouse embryonic stem cell genomeREGENERON PHARMA·Filed 2016·Granted Feb 19, 2019·15 cites·61 claims
- 0698US8697851B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2012·Granted Apr 15, 2014·91 cites·9 claims
- 0798US8354389B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2010·Granted Jan 15, 2013·56 cites·13 claims
- 0897US9155290B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2014·Granted Oct 13, 2015·27 cites·4 claims
- 0996US10301646B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2017·Granted May 28, 2019·12 cites·28 claims
- 1096US8518392B2Promoter-regulated differentiation-dependent self-deleting cassetteFRENDEWEY DAVID·Filed 2010·Granted Aug 27, 2013·57 cites·11 claims
- 1195US10711280B2Methods and compositions for the targeted modification of a mouse ES cell genomeREGENERON PHARMA·Filed 2018·Granted Jul 14, 2020·5 cites·69 claims
- 1295US9738897B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Aug 22, 2017·13 cites·29 claims
- 1394US9834786B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2013·Granted Dec 5, 2017·13 cites·34 claims
- 1494US8946505B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·11 claims
- 1594US8946504B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·16 claims
- 1693US10975390B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2019·Granted Apr 13, 2021·4 cites·46 claims
- 1793US9580715B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2015·Granted Feb 28, 2017·7 cites·30 claims
- 1892US9267152B2MiRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2015·Granted Feb 23, 2016·4 cites·29 claims
- 1991US10457960B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2015·Granted Oct 29, 2019·5 cites·53 claims
- 2090US9096870B2miRNA-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 4, 2015·6 cites·13 claims
- 2189US10781453B2Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locusREGENERON PHARMA·Filed 2017·Granted Sep 22, 2020·6 cites·48 claims
- 2289US10390522B2Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2015·Granted Aug 27, 2019·6 cites·15 claims
- 2389US9410163B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 9, 2016·3 cites·12 claims
- 2489US2024052365A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2588US10894965B2Genetic modification of ratsREGENERON PHARMA·Filed 2019·Granted Jan 19, 2021·2 cites·39 claims
- 2687US10561125B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2017·Granted Feb 18, 2020·2 cites·6 claims
- 2787US2024229048A1Nuclease-mediated dna assemblyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2886US9913461B2Genetically modified mouse whose genome comprises a humanized CD274 geneREGENERON PHARMA·Filed 2015·Granted Mar 13, 2018·4 cites·19 claims
- 2986US2024389563A1Genetically modified mouse that expresses humanized pd1 and pd-l1 proteinsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3085US12419282B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2024·Granted Sep 23, 2025·0 cites·20 claims
- 3185US10881086B2Genetically modified mouse whose genome comprises a humanized CD274 geneREGENERON PHARMA·Filed 2018·Granted Jan 5, 2021·2 cites·10 claims
- 3284US11589562B2Mouse model of DITRA disease and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 28, 2023·2 cites·27 claims
- 3383US11684050B2Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2019·Granted Jun 27, 2023·1 cites·14 claims
- 3483US10626402B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2019·Granted Apr 21, 2020·1 cites·52 claims
- 3582US10273488B2Nuclease-mediated DNA assemblyREGENERON PHARMA·Filed 2017·Granted Apr 30, 2019·1 cites·31 claims
- 3682US2024298619A1Non-human animals having a humanized programmed cell death 1 geneREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3781US12369570B2Humanized IL-15 animalsREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·6 claims
- 3880US11470828B2Rodent model of mood disordersREGENERON PHARMA·Filed 2020·Granted Oct 18, 2022·1 cites·24 claims
- 3980US10548302B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·1 cites·30 claims
- 4080US2023332185A1Methods and compositions for targeted genetic modification using paired guide rnasREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4179US11697828B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2019·Granted Jul 11, 2023·1 cites·33 claims
- 4278US12037596B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·5 claims
- 4377US2025280805A1Methods for producing antigen-binding proteins against foreign antigensREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4476US12065661B2Genetic modification of ratsREGENERON PHARMA·Filed 2020·Granted Aug 20, 2024·0 cites·21 claims
- 4576US11820997B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2020·Granted Nov 21, 2023·0 cites·73 claims
- 4676US2023189771A1Lincrna-deficient non-human animalsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4774US12342801B2Methods for producing antigen-binding proteins against foreign antigensREGENERON PHARMA·Filed 2021·Granted Jul 1, 2025·0 cites·20 claims
- 4874US10285388B2Non-human animals having a disruption in a C9ORF72 locusREGENERON PHARMA·Filed 2016·Granted May 14, 2019·2 cites·30 claims
- 4973US12089575B2Genetically modified mouse that expresses humanized PD1 and PD-L1 proteinsREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·0 cites·7 claims
- 5073US11937587B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2020·Granted Mar 26, 2024·0 cites·19 claims
Showing the top 50 of 78 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ka-Man Venus Lai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →